Back to today’s briefing

Story perspectives

Aldeyra Resubmits Dry Eye Drug Application with New Data

6/18/2025

25 5

Summary

Story summary

Aldeyra Therapeutics is back in the spotlight, resubmitting its new drug application for reproxalap, a topical solution aimed at alleviating dry eye disease. After previous setbacks due to efficacy concerns, the latest submission boasts fresh clinical data from a promising trial, offering hope to the 16.4 million Americans grappling with this condition.

1 of 1

Story summary

Aldeyra Therapeutics is back in the spotlight, resubmitting its new drug application for reproxalap, a topical solution aimed at alleviating dry eye disease. After previous setbacks due to efficacy concerns, the latest submission boasts fresh clinical data from a promising trial, offering hope to the 16.4 million Americans grappling with this condition.